ALECTOR INC (ALEC)
Health Care · biotechnology · NASDAQ
Alector is a biotech firm pioneering blood-brain barrier delivery technologies to advance a diverse pipeline of therapeutic candidates for neurodegenerative diseases.
What ALECTOR INC does
Alector is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases, including Alzheimer's and Parkinson's. Its proprietary Alector Brain Carrier (ABC) platform is a blood-brain barrier delivery technology designed to enable the transport of antibodies, enzymes, and siRNA across the central nervous system. The company's pipeline consists of candidates targeting genetically validated drivers of neurodegeneration, such as amyloid-beta, tau, alpha-synuclein, and GCase enzyme deficiency.
Recent developments
In April 2026, GSK discontinued the Phase 2 trial of nivisnebart (AL101) after an interim analysis showed it was unlikely to meet primary endpoints. Subsequently, on July 6, 2026, GSK provided notice of termination for its collaboration with Alector. The company has shifted focus to advancing its next-generation ABC-enabled preclinical pipeline, specifically the AL137 (anti-amyloid beta), AL064/AL164 (tau siRNA), and AL050 (GCase enzyme replacement) programs.
From ALECTOR INC's filing of 2026-08-06.
Themes: neurodegeneration, blood-brain barrier delivery, Alzheimer's disease, Parkinson's disease, gene-targeted therapies, siRNA therapeutics
Fundamentals
- Price$2.02 as of 2026-10-08 close
- Market cap$226M as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return-34.4% 2025-10-08 close $3.08 → 2026-10-08 close $2.02
- P/En/a negative earnings
- Net margin-679.2% FY2025, SEC XBRL
- ROE-466.3% FY2025, SEC XBRL
- Debt / equity0.94 as of 2026-09-03
- Revenue growth (YoY)-79.2% as of 2026-09-03
- Revenue CAGR (3y)-46.0% SEC XBRL
- Beta1.55 as of 2026-09-03
- Last reported earnings2026-10-05 SEC EDGAR Form 8-K (Item 2.02)
How ALEC compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-03
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ALECTOR INC looks technically
ALECTOR INC (ALEC) is trading 1.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 11 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It made a new 20-day low about 5 trading days ago. It is 40.6% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 7% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 1.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +1.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.05 | $2.05 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.00 | $2.00 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 20 calendar days ago — the swings before that are what the structure reading is measured on | 20 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 11 trading days ago — a "golden cross", a bullish long-term signal | 11 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 1.0% above | +1.0% |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend) | 23.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30) | 51.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($1.73 to $2.73) — its "stochastic" reading is 29 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 29.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $3.40 | $3.40 |
|---|---|---|
| From the 52-week high | it is 40.6% below its 52-week high (its highest price of the past year) | -40.6% |
| Above the 52-week low | it is 85.3% above its 52-week low (its lowest price of the past year) | +85.3% |
| Below the 52-week high | it is 40.6% below its highest point of the past year | 40.6% |
| Since a 20-day breakout | it made a new 20-day low about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day high about 26 trading days ago | 26 sessions |
| All-time high | its highest closing price on record is $43.32 (set on 2021-07-02) | $43.32 |
| Given back of the 52-week move | over the past year its closes ranged ($1.14 to $3.32), and it has recovered roughly a third of its fall from last year’s high — 40% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.49 to $2.56. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 40.4% |
| From the all-time high | it is 95.3% below its all-time high | -95.3% |
| Nearest price level | it is trading 0.8% above a support level at $2.00 — a price it turned at four times since 2024-12-05, most recently on 2026-05-21. Since 2024-10-08 it has 9 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.8% |
| All-time low | its lowest closing price on record is $0.87 (set on 2025-04-09) | $0.87 |
| Above the all-time low | it is 132.2% above its all-time low | +132.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 7% of the past ~6 months), which often precedes a bigger move | 7th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2219 between its high and its low — about 11.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2219 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.75 and $2.15 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.75 – $1.95 – $2.15 |
| Typical daily range (% of price) | its price moves about 11.0% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 11.0% |
| Stretch from the 200-day average | it is trading 0.1 daily ranges above its 200-day average price (1.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.39× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|---|---|
| Since a bearish engulfing | 4 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 4 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 1.0% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.0% |
|---|---|---|
| Gap filled | a 4.5% gap up opened on 2026-10-06 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +11.6% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 19.3 percentage points (the stock lost 18.2% while the market gained 1.0%) | -19.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 6.6 percentage points (the stock gained 10.4% while the market gained 3.8%) | +6.6% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 31.3 percentage points (the stock lost 13.9% while the market gained 17.5%) | -31.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 49.4 percentage points (the stock lost 34.4% while the market gained 15.0%) | -49.4% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: lagging the market over 6 months — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 11.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is sitting right on the average price paid so far this year, so the typical buyer over that stretch is roughly break-even. That average is $2.02 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +0.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is roughly break-even. That average is $2.03 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -0.4% |
Price levels it has turned at before
ALEC last closed at $2.02 on 2026-10-08. Since 2024-10-08 it has turned at 9 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.00 | Support | 0.8% below the last close | turned there four times · 2024-12-05 to 2026-05-21 |
| $1.95 | Support | 3.5% below the last close | turned there three times · 2025-01-27 to 2026-03-30 |
| $2.15 | Resistance | 6.6% above the last close | turned there three times · 2025-01-06 to 2026-07-02 |
| $1.75 | Support | 13.6% below the last close | turned there twice · 2025-07-10 to 2026-02-05 |
| $2.30 | Resistance | 13.8% above the last close | turned there three times · 2025-09-02 to 2026-05-26 |
| $2.51 | Resistance | 24.4% above the last close | turned there twice · 2025-08-14 to 2026-08-19 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Near 200-day moving-average support · Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · in a Bollinger Band volatility squeeze | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.57 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$3.30 range $1.00 – $6.00; median $3.00
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ALEC
- Consensus EPS estimate-$0.21 next reporting period, as of 2026-10-09
- Estimate change, 30 days+$0.01833 from -$0.2283, on 2026-09-07, 32-day window
- Readings revised upward22% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy reliance on developing novel, unproven technologies (ABC platform) with no approved products.","Significant operating losses since inception and continued need for additional capital to fund operations.","Increased risk of portfolio disruption following the termination of the GSK collaboration and discontinuation of the nivisnebart program."]
What changed in the latest 10-Q
AI-assisted comparison of ALEC's 10-Q filed 2026-08-06 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-06) adds that the ABC platform 'supports efficient delivery of therapeutic cargos across the BBB' and can be tailored to different therapeutic modalities while 'preserving the ability to recruit the brain's immune system when desired.'
- Newer filing (2026-08-06) adds that AL137 is designed to 'minimiz[e] treatment-related adverse effects and enabl[e] convenient subcutaneous administration.'
- Newer filing (2026-08-06) adds that the ABC platform was engineered to reduce TfR co-engagement on reticulocytes and peripheral immune cells while preserving Fc-mediated engagement of immune cells at Aβ plaques, intended to achieve efficient plaque clearance while minimizing hematologic adverse effects.
- Newer filing (2026-08-06) adds that AL137 selectively binds pyroglutamate-3 Aβ (PyroGlu3 Aβ), a validated and pathogenic form of Aβ enriched in amyloid plaques.
- Newer filing (2026-08-06) adds that a murine surrogate has shown significant reduction of brain Aβ42 levels in Alzheimer's disease mouse models.
- Newer filing (2026-08-06) adds that following comparative evaluation, AL137 was selected as the lead development candidate and subcutaneous administration as the intended clinical route, with AL037 designated as backup.
- Newer filing (2026-08-06) adds a target for first-in-human dosing in Australia no later than April 2027.
- Newer filing (2026-08-06) adds that the ABC-enabled siRNA platform offers potential for 'more convenient and scalable administration' compared with traditional intrathecal delivery.
- Newer filing (2026-08-06) adds that AL064 demonstrated 'homogeneous' tau mRNA knockdown in multiple NHP brain regions tested.
- Newer filing (2026-08-06) adds that AL050 can be a 'disease modifying therapy' for Parkinson's disease and Lewy body dementia.
- Newer filing (2026-08-06) adds that GSK provided written notice of termination of the collaboration on July 6, 2026.
- Removed:
- Older filing (2026-05-07) includes reference to addressing disease through 'misfolded or deficient proteins, lysosomal dysfunction, and immune and neuronal pathway disruption.'
- Older filing (2026-05-07) includes reference to support from 'our experience in drug development, protein engineering, antibody discovery, and biomarker assessment.'
- Older filing (2026-05-07) includes that ABC is intended to optimize safety and efficacy 'at lower doses' and achieve efficient transport 'with the goal of balancing brain uptake, potency, and safety.'
- Older filing (2026-05-07) describes AL037/AL137 as being 'in preclinical development' and designed to minimize 'treatment-related incidence and/or severity of amyloid-related imaging abnormalities (ARIA), and to enable subcutaneous delivery.'
- Older filing (2026-05-07) includes that AL037 and AL137 feature the same high-affinity antibody, a 'fully active effector function,' TfR binding domains binding the same TfR epitope with different affinities and kinetics, and that a murine surrogate demonstrated 'amyloid beta 42 reduction in murine studies.'
- Older filing (2026-05-07) includes that following IND-enabling studies, the company intended to 'select AL037 or AL137' for IND submission.
- Older filing (2026-05-07) describes the siRNA platform as offering potential for 'more convenient administration' but omits 'scalable administration.'
- Older filing (2026-05-07) describes AL064/AL164 as aiming to 'prevent the synthesis of tau mRNA and protein, with the goal of removing toxic tau, suppressing tau protein expression, and slowing cognitive decline in AD.'
- Older filing (2026-05-07) describes AL064 as demonstrating robust tau mRNA knockdown and durable phospho-Tau 217 reduction 'in NHP brains' without specifying homogeneous or multiple brain regions tested.
- Older filing (2026-05-07) describes AL050 preclinical data as showing reduced toxic substrate accumulation 'without abnormal hematologic findings.'
- Older filing (2026-05-07) describes AL050 as selected 'as a lead candidate,' rather than 'as the lead candidate.'
- Reworded:
- The newer filing (2026-08-06) reframes the company description from 'developing therapies for neurodegenerative diseases, with a focus on areas of high unmet medical need' to 'focused on discovering and developing therapies... including Alzheimer's disease and Parkinson's disease,' and states the pipeline is 'wholly owned.'
- The newer filing (2026-08-06) replaces the older overview's description of the ABC platform with a new paragraph emphasizing 'brain exposure,' 'safety and efficacy,' 'efficient delivery,' and 'recruit[ing] the brain's immune system when desired.'
- The newer filing (2026-08-06) changes the program heading from 'AL037/AL137 Program' to 'AL137 Program.'
- The newer filing (2026-08-06) changes AL137's Aβ antibody description from binding 'PyroGlu3, a validated epitope on the toxic form of Aβ found in plaques' to binding 'pyroglutamate-3 Aβ (PyroGlu3 Aβ), a validated and pathogenic form of Aβ enriched in amyloid plaques.'
- The newer filing (2026-08-06) changes AL064/AL164's mechanism from 'prevent the synthesis of tau mRNA and protein' to 'reduce all forms of toxic tau by degrading tau mRNA and reducing tau protein expression and slow cognitive decline in AD and other tauopathies.'
- The newer filing (2026-08-06) changes AL050's BBB description from 'a TfR epitope and affinity designed to enhance delivery across the BBB' to 'a TfR epitope with affinity designed to enhance delivery across the BBB.'
- The newer filing (2026-08-06) changes the nivisnebart discontinuation description from 'after a pre-specified interim futility analysis... which concluded' to 'following a pre-specified interim futility analysis... The IDMC concluded.'
- The newer filing (2026-08-06) changes the financing description from 'our collaboration with GSK' to 'our collaboration with GSK, for which GSK provided written notice of termination on July 6, 2026.'
- Notes:
- The newer filing text appears truncated at the end ('fund operations for the fore'), and the older filing text also appears truncated ('develop our product candida'), so changes after those points cannot be assessed.
- No other sections of the filings were provided, so comparisons are limited to the extracted MD&A passages.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 5 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 5 sells ($296087) — 3 selling insiders
- Last 180 days · read to 2026-10-040 buys · 10 sells ($529134) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-04. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ALEC's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ALEC as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 13,059,472
- Reported value $26,249,537
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ALEC's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ALEC had 6,104,803 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
ALEC had 5.47% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.34 days to cover at the same settlement.
- Reported short interest (shares) 6,104,803
- Short interest (% of shares outstanding) 5.47%
- Prior settlement (shares) 6,165,227
- Reported change -0.98%
- Days to cover (reported) 3.34
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Biogen (BIIB)
- Eli Lilly (LLY)
- Eisai (ESALY)
- Roche (RHHBY)
- Denali Therapeutics (DNLI)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ALEC vs…
Frequently asked questions
What does ALECTOR INC (ALEC) do?
Alector is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases, including Alzheimer's and Parkinson's. Its proprietary Alector Brain Carrier (ABC) platform is a blood-brain barrier delivery technology designed to enable the transport of antibodies, enzymes, and siRNA across the central nervous system.
What sector is ALECTOR INC (ALEC) in?
ALECTOR INC (ALEC) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are ALECTOR INC's (ALEC) competitors?
Notable peers of ALECTOR INC (ALEC) include Biogen, Eli Lilly, Eisai, Roche and Denali Therapeutics. This peer set is informational only — not financial advice.
Is ALECTOR INC (ALEC) overbought or oversold right now?
ALECTOR INC (ALEC) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 51, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ALEC come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.